Finance

Lists
GIS:FRA
Gilead Sciences, Inc
၁၃၆.၁၀ €
+၁.၅၇%
(+၂.၁၀) 1D
အောက် ၁၄, GMT+၂ ၂၂:၀၀:၀၀  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GIS...
Open
၁၃၁.၅၆ €
High
၁၃၆.၁၀ €
Low
၁၃၁.၅၆ €
Mkt. cap
ဋေ ၁.၉၀ သ
Avg. vol.
၄၂၃.၀၀
Volume
၂၅၀.၀၀
52-wk high
၁၃၆.၁၀ €
52-wk low
၉၇.၇၉ €
No. of employees
၂ သောင်း
Open
၁၃၁.၅၆ €
High
၁၃၆.၁၀ €
Low
၁၃၁.၅၆ €
Mkt. cap
ဋေ ၁.၉၀ သ
Avg. vol.
၄၂၃.၀၀
Volume
၂၅၀.၀၀
52-wk high
၁၃၆.၁၀ €
52-wk low
၉၇.၇၉ €
No. of employees
၂ သောင်း
News stories
From web sources and news partners
The Business Journals
The Business Journals
·
ပြီးခဲ့သည့် ၂ နာရီ
In potential $1.9 billion deal, Gilead and Vir look to broaden attack on cancers
Kalkine Media
Kalkine Media
·
ပြီးခဲ့သည့် ၃ နာရီ
Gilead Sciences (NASDAQ:GILD): What Changes After Its Latest Company Update?
MarketBeat
MarketBeat
·
ပြီးခဲ့သည့် ၄ နာရီ
Gilead Sciences (NASDAQ:GILD) Stock Price Up 3.9% - What's Next?
StocksToTrade
StocksToTrade
·
ပြီးခဲ့သည့် ၅ နာရီ
Gilead Sciences Stock Draws Wave Of Bullish Target Hikes
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees၁.၇ သောင်း
Founded၁၉၈၇ ဇွန် ၂၂
HeadquartersFoster City, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitegilead.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၇၇၆.၉၀ ဋေ
၇၉၂.၅၀ ဋေ
၆၉၆.၀၀ ဋေ
၇၈၀.၃၀ ဋေ
Cost of goods sold
၁၅၆.၉၀ ဋေ
၁၆၂.၀၀ ဋေ
၁၄၄.၅၀ ဋေ
၁၅၇.၉၀ ဋေ
Cost of revenue
၁၅၆.၉၀ ဋေ
၁၆၂.၀၀ ဋေ
၁၄၄.၅၀ ဋေ
၁၅၇.၉၀ ဋေ
Research and development expenses
၁၃၃.၄၀ ဋေ
၁၅၆.၆၀ ဋေ
၁၃၅.၅၀ ဋေ
၁၆၉.၀၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၃၅.၂၀ ဋေ
၁၇၇.၇၀ ဋေ
၁၄၂.၆၀ ဋေ
၁၉၀.၆၀ ဋေ
Operating expense
၂၆၈.၆၀ ဋေ
၃၃၄.၃၀ ဋေ
၂၇၈.၁၀ ဋေ
၃၅၉.၆၀ ဋေ
Total operating expenses
၄၂၅.၅၀ ဋေ
၄၉၆.၃၀ ဋေ
၄၂၂.၆၀ ဋေ
၅၁၇.၅၀ ဋေ
Operating income
၃၅၁.၄၀ ဋေ
၂၉၆.၂၀ ဋေ
၂၇၃.၄၀ ဋေ
၂၆၂.၈၀ ဋေ
Other non operating income
-၂.၃၀ ကုဋေ
၅.၁၀ ကုဋေ
-၈.၀၀ သန်း
-
EBT including unusual items
၃၆၄.၁၀ ဋေ
၂၀၇.၈၀ ဋေ
၂၅၈.၀၀ ဋေ
-ဋေ ၁.၀၃ ထ
EBT excluding unusual items
၃၃၄.၅၀ ဋေ
၂၈၀.၃၀ ဋေ
၂၅၈.၇၀ ဋေ
၂၄၂.၅၀ ဋေ
Income tax expense
၅၈.၉၀ ကုဋေ
-၁၀.၅၀ ကုဋေ
၅၅.၉၀ ကုဋေ
၂၄.၂၀ ကုဋေ
Effective tax rate
၁၆.၁၈%
-၅.၀၅%
၂၁.၆၇%
-၂.၃၆%
Other operating expenses
-
-
-
-
Net income
၃၀၅.၂၀ ဋေ
၂၁၈.၃၀ ဋေ
၂၀၂.၁၀ ဋေ
-ဋေ ၁.၀၅ ထ
Net profit margin
၃၉.၂၈%
၂၇.၅၅%
၂၉.၀၄%
-၁၃၄.၅၁%
Earnings per share
၂.၄၇
၁.၈၆
၂.၀၃
-၆.၇၅
Interest and investment income
၈.၈၀ ကုဋေ
၉.၅၀ ကုဋေ
၉.၅၀ ကုဋေ
၄.၅၀ ကုဋေ
Interest expense
-၂၅.၆၀ ကုဋေ
-၂၅.၅၀ ကုဋေ
-၂၄.၀၀ ကုဋေ
-၂၄.၇၀ ကုဋေ
Net interest expenses
-၁၆.၈၀ ကုဋေ
-၁၆.၀၀ ကုဋေ
-၁၄.၅၀ ကုဋေ
-၂၀.၂၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၄၂၀.၀၀ ဋေ
၃၆၄.၉၀ ဋေ
၃၄၂.၃၀ ဋေ
၃၃၂.၆၀ ဋေ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google အက်ပ်များ